On 5 November 2018, the current EU GDP Guideline turned five years old. What have we learned in those five years? Have we succeeded in achieving a better protection of the integrity of pharmaceutical products and fortified patient safety? What did it mean for the R&D industry, the drug manufacturers and their service partners in the supply chain?

Logistics by Design (LbD) is a framework for logistics decision making. Using a risk based analysis it identifies the areas within the supply chain that need to be addressed to create a logistics platform that can meet the needs of patients at clinical and commercial scale.